No connection

Search Results

IART vs MGTX

IART
Integra LifeSciences Holdings Corporation
NEUTRAL
Price
$9.90
Market Cap
$771.6M
Sector
Healthcare
AI Confidence
85%
MGTX
MeiraGTx Holdings plc
NEUTRAL
Price
$9.63
Market Cap
$784.3M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
IART
--
MGTX
--
Forward P/E
IART
3.86
MGTX
-14.48
P/B Ratio
IART
0.74
MGTX
-135.63
P/S Ratio
IART
0.47
MGTX
9.64
EV/EBITDA
IART
8.54
MGTX
-8.64

Profitability

Gross Margin
IART
56.23%
MGTX
94.05%
Operating Margin
IART
12.44%
MGTX
35.13%
Profit Margin
IART
-31.58%
MGTX
-140.31%
ROE
IART
-39.9%
MGTX
-368.19%
ROA
IART
2.39%
MGTX
-25.76%

Growth

Revenue Growth
IART
-1.7%
MGTX
252.3%
Earnings Growth
IART
--
MGTX
--

Financial Health

Debt/Equity
IART
1.95
MGTX
--
Current Ratio
IART
2.54
MGTX
0.75
Quick Ratio
IART
1.19
MGTX
0.69

Dividends

Dividend Yield
IART
--
MGTX
--
Payout Ratio
IART
0.0%
MGTX
0.0%

AI Verdict

IART NEUTRAL

IART presents as a classic deep-value turnaround candidate with a stable Piotroski F-Score of 6/9, indicating reasonable operational health despite severe price depreciation. The company is trading at a significant discount to book value (P/B 0.74) and possesses a very low forward P/E of 3.86, suggesting the market has over-priced the risk. However, negative net profit margins (-31.58%) and stagnant revenue growth (-1.70%) offset the valuation appeal. The stark contrast between the current price ($9.90) and the analyst target ($15.57) indicates potential upside, but the bearish technical trend remains a primary headwind.

Strengths
Deep value valuation with P/B of 0.74 and P/S of 0.47
Strong short-term liquidity with a Current Ratio of 2.54
Stable financial health baseline (Piotroski F-Score 6/9)
Risks
Severe long-term price erosion (-85.7% over 5 years)
Negative net profit margins (-31.58%) impacting bottom-line stability
Stagnant to declining revenue growth (YoY -1.70%)
MGTX NEUTRAL

MGTX presents a stark dichotomy between catastrophic financial health and explosive growth. The deterministic baseline is severely weak, highlighted by a Piotroski F-Score of 1/9 and a negative Price-to-Book ratio, indicating significant insolvency risk and poor operational efficiency. However, the company is experiencing massive revenue growth (252% YoY) and has strong analyst backing with a $26 target price. The investment profile is purely speculative, relying on future commercial success to offset current balance sheet distress.

Strengths
Exceptional revenue growth of 252.30% YoY
Very high gross margins (94.05%) typical of high-value biotech
Strong analyst consensus with a 'strong_buy' recommendation
Risks
Critical financial health indicated by Piotroski F-Score of 1/9
Liquidity risk with a current ratio of 0.75 (below 1.0)
Negative equity as evidenced by a Price/Book of -135.63

Compare Another Pair

IART vs MGTX: Head-to-Head Comparison

This page compares Integra LifeSciences Holdings Corporation (IART) and MeiraGTx Holdings plc (MGTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile